About me

I am a health economist and British Academy Postdoctoral Fellow at the Department of Economics & Public Policy, Imperial College London, where I lead an independent three-year research programme on drug repurposing. My research focuses on pharmaceutical innovation, health technology assessment (HTA) and access to medicines.

Before the fellowship, I was a Postdoctoral Research Associate at Imperial College London, where I was co-investigator on a Gatsby Foundation project on the productivity of UK biopharmaceutical R&D and contributed to the EU-funded Hi-Prix project on pharmaceutical innovation and equitable access. I completed my ESRC-funded PhD at the London School of Economics, studying the role of patient organisations in innovation and access to medicines for rare diseases.

My work uses both quantitative and qualitative methods, including econometrics, survival analysis, document analysis and interviews. It has been published in journals such as The Lancet Oncology, The BMJ, Social Science & Medicine and Value in Health, and has been covered by The Observer. Beyond academia, I have worked as a health economist at NICE, as a consultant for the World Bank, and in health economics and market access consultancies.

Contact

a.gentilini@imperial.ac.uk
arianna.gentilini.ag@gmail.com

Research

My research asks how policy, institutions and stakeholders shape which medicines are developed, how they are valued, and who gets access to them.

Current and recent projects

Drug repurposing Since 2026 British Academy Postdoctoral Fellowship, Imperial College London (£580,176). Principal investigator.
Drug Development Productivity: The Performance of the UK Biopharmaceutical Industry 2024–2026 Gatsby Foundation (£154,317). Co-investigator.
Hi-Prix: Incentives for pharmaceutical innovation and equitable access 2024–2026 EU Horizon Europe. Comparative policy analysis of innovation incentives across countries.
IMPACT HTA 2020–2024 EU-funded. Drivers of reimbursement timelines and outcomes across OECD countries.

Awards and funding

  • British Academy Postdoctoral Fellowship, 2026
  • Highly Commended, LSE Class Teacher Awards, 2023–24
  • “Italy Made Me” award for outstanding research by Italian early-career researchers in the UK, 2023
  • ESRC Doctoral Training Partnership studentship, 2020–2024

Publications

For an up-to-date list with citations, see my Google Scholar profile.

Peer-reviewed articles

Under review

  • Do policy incentives align with pharmaceutical innovation challenges? A retrospective analysis of 42 countries (2000–2022)
    Mermelstein S, Gentilini A, Stevens H, Miraldo M. Submitted to Health Affairs.

Selected reports and abstracts

Media coverage

Teaching

University of Bologna

Imperial College London

  • Health Economics (MSc)
    Seminar leader, 2023 & 2024 · Prof. Marisa Miraldo; Prof. Laure de Preux
  • Research Methods & Practice (BSc)
    Seminar leader, 2023 · Prof. Sam Asher
  • Quantitative Methods (PhD)
    Seminar leader, 2023 · Prof. Paola Criscuolo
  • Health Care Financing (MSc)
    Seminar leader, 2022 · Prof. Pedro Rosa Dias

London School of Economics

  • Pharmaceutical Economics and Policy (MSc)
    Seminar leader, 2024 · Prof. Panos Kanavos
  • Introduction to Quantitative Analysis (MSc)
    Seminar leader, 2021 · Prof. Patrick Sturgis
  • Intermediate Quantitative Analysis (MSc/PhD)
    Seminar leader, 2021 · Prof. Patrick Sturgis
  • Market Access Academy (Executive education)
    Class teacher, 2023–2024 · LSE Health with Boston Consulting Group

Talks & service

Talks and conferences

  • Technology adoption in clinical trials: a global retrospective analysis of artificial intelligence and digital-health tools, 1990–2024
    Oral presentation, Associazione Italiana Economia Sanitaria (AIES), Verona, December 2025
  • Assessing value of medicines: the example of HTA
    Invited speaker, 8th Global Conference on Creating Value, London, November 2025
  • Do patient inputs matter? A thematic document analysis of NICE ultra-rare disease appraisals
    Poster, HTAi Annual Meeting, Seville, June 2024
  • The role of patient organisations on research and development: evidence from rare diseases
    Poster, American-European Health Economics Study Group, Harvard Kennedy School, July 2023
  • Leveraging pharmaceutical services to enhance NCD service delivery in LMICs: insights from Zambia
    Poster, World Non-Communicable Diseases Congress, Toronto, June 2023
  • Industry funding of patient organisations in the United Kingdom
    Invited speaker, Connaught Global Challenge Award Seminar Series, WHO Collaborating Centre for Governance, Accountability and Transparency in the Pharmaceutical Sector (virtual), March 2023

Service

  • Ad-hoc reviewer: BMJ, Health Policy, Health Policy and Technology
  • Organiser, Workshop on Corruption and Conflicts of Interest in Healthcare, LSE, January 2024
  • Co-founder, LSE–LSHTM Rare Diseases Reading Group, 2021–2024
  • Member, Royal Economic Society